Express News | NewAmsterdam Pharma Announces Appointments of Mark C. Mckenna and Wouter Joustra to Its Board of Directors
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday.Shares of Methode Electronics, Inc. (NYSE:MEI) rose sharply during Thursday's session after the company
Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE)
Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)
Apogee Therapeutics(APGE.US) Officer Sells US$225.42K in Common Stock
$Apogee Therapeutics(APGE.US)$ Officer Dambkowski Carl sold 5,995 shares of common stock on Jul 3, 2024 at an average price of $37.6 for a total value of $225.42K.Source: Announcement What is statemen
Apogee Therapeutics(APGE.US) Officer Sells US$558.9K in Common Stock
$Apogee Therapeutics(APGE.US)$ Officer HENDERSON MICHAEL THOMAS sold 15,000 shares of common stock on Jul 5, 2024 at an average price of $37.26 for a total value of $558.9K.Source: Announcement What i
Form 144 | Apogee Therapeutics(APGE.US) Officer Proposes to Sell 558.92K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 5, $Apogee Therapeutics(APGE.US)$ Officer HENDERSON MICHAEL THOMAS intends to sell 15,000 shares of its common stock on Jul 5, with a total market value of approximately $5
Form 144 | Apogee Therapeutics(APGE.US) Officer Proposes to Sell 916.28K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 3, $Apogee Therapeutics(APGE.US)$ Officer CARL DAMBKOWSKI intends to sell 23,980 shares of its common stock on Jul 3, with a total market value of approximately $916.28K.
We Think Apogee Therapeutics (NASDAQ:APGE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Apogee Therapeutics Welcomes Dr. Bollinger to Board
Express News | Apogee Therapeutics Expands Board of Directors With the Appointment of Lisa Bollinger, Md
Here's Why We're Not Too Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Situation
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic
Apogee Therapeutics Starts Phase 2 Trial for Atopic Dermatitis Drug
Express News | Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of Apg777, a Novel Subcutaneous Half-Life Extended Anti-Il-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Buy Rating on Apogee Therapeutics: Promising Drug Developments and Strong Financials
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Apogee Therapeutics, Inc. (APGE)